PPARG and autosomal dominant polycystic kidney disease: Moreover, PPARγ agonists have been also shown to reduce renal damage in animal models of ischemia reperfusion injury, autosomal dominant polycystic kidney disease (ADPKD) or nondiabetic chronic kidney diseases [19].